Publication:
Modeling Schizophrenia with Glioblastoma Cells: In Vitro Analysis of Risperidone Treatment on Glial Spheroids

Simple item page
dc.contributor.authorSomuncu, Özge Sezin
dc.contributor.authorKaraman, İrem
dc.contributor.authorSaraçoğlu, Hilal Pırıl
dc.contributor.authorYılmaz, Erdem
dc.contributor.authorAkın, Demet
dc.contributor.institutionYabancı Kurumlar
dc.contributor.institutionYabancı Kurumlar
dc.contributor.institutionKOÇ ÜNİVERSİTESİ
dc.contributor.institutionBAHÇEŞEHİR ÜNİVERSİTESİ
dc.contributor.institutionBAHÇEŞEHİR ÜNİVERSİTESİ
dc.date.accessioned2025-09-20T19:58:31Z
dc.date.issued2021
dc.date.submitted10.05.2023
dc.description.abstractObjective: Glioblastoma is the most malicious type of glioma presenting a genetic background via diverse mutations and exhibits differential sensitivity to treatment. Meanwhile, schizophrenia is a heterogeneous disease with a complex etiology. Studies report an elevation in pro-inflammatory cytokines in patients with schizophrenia and changes in biochemical metabolism. In the present study, the tumor spheroid technology is applied to two different glioblastoma lines which resemble schizophrenia manifestation along with the investigation of the potential anti-tumor effect of an atypical antipsychotic drug, risperidone. Our hypothesis built on case reports showing patients with schizophrenia being treated with risperidone that turned out to have glioblastoma in post-mortem evaluation. Risperidone has been suggested to carry therapeutic effects for glioblastoma and elongated lifespan after the diagnosis of cancer. Materials and Methods: In this current study, 3D models using C6 and U87 glioblastoma cells and monocytes for representing the disease grown as multicellular spheroids were established. Spheroids were treated with the anti-schizophrenic agent risperidone and indicated almost similar results to the clinics suggesting that glioblastoma and schizophrenia share mutual physiological characteristics. Results: U87 and C6 spheroid systems were analyzed molecularly after the treatment of risperidone where U87 spheroid models were found highly resembling the overall behavior of schizophrenia. This present work correlated the stated two diseases in molecular level to encourage the efforts for personalized medicine. Conclusion: The anti-tumor effects of risperidone on glioblastoma is not very well established yet. It should not be missed that a picture of schizophrenia in clinics may be the result of an underlying lesion in a specific brain area. Thus, especially schizophrenia patients who may be at risk for developing brain tumors should be further investigated and treated accordingly.
dc.identifier.doi10.5152/pcp.2021.20181
dc.identifier.endpage59
dc.identifier.issn2475-0581
dc.identifier.issue1
dc.identifier.startpage48
dc.identifier.urihttps://hdl.handle.net/20.500.14719/5002
dc.identifier.volume31
dc.language.isoen
dc.relation.journalPsychiatry and clinical psychopharmacology (Online)
dc.subjectTıbbi Araştırmalar Deneysel
dc.subjectKlinik Nöroloji
dc.subjectOnkoloji
dc.subjectHücre Biyolojisi
dc.subjectFarmakoloji ve Eczacılık
dc.subjectTıbbi Laboratuar Teknolojisi
dc.subjectPsikiyatri
dc.titleModeling Schizophrenia with Glioblastoma Cells: In Vitro Analysis of Risperidone Treatment on Glial Spheroids
dc.typeResearch Article
dcterms.references1. Seppala J, Miettunen J, Jääskeläinen E, et al. Definition, epidemiology, clinical course and outcomes in treatment resistant schizophrenia. Eur Psychiatr. 2017,41(S1):S67-S67. [CrossRef],2. Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016. Schizophr Bull. 2018,44(6):1195-1203. [CrossRef],3. Stachowiak EK, Benson CA, Narla ST, et al. Cerebral organoids reveal early cortical maldevelopment in schizophrenia-computational anatomy and genomics, role of FGFR1. Transl Psychiat. 2017,7(11):6. [CrossRef],4. Bunevicius A, Deltuva VP, Deltuviene D, Tamasauskas A, Bunevicius R. Brain lesions manifesting as psychiatric disorders: eight cases. CNS Spectr. 2008,13(11):950-958. [CrossRef],5. Henriksen MG, Nordgaard J, Jansson LB. Genetics of schizophrenia: overview of methods, findings and limitations. Front Hum Neurosci. 2017,11:322. [CrossRef],6. Modai S, Shomron N. Molecular risk factors for schizophrenia. Trends Mol Med. 2016,22(3):242-253. [CrossRef],7. Serafini G, Pompili M, Haghighat R, et al. Stigmatization of schizophrenia as perceived by nurses, medical doctors, medical students and patients. J Psychiatr Ment Hlt. 2011,18(7):576-585. [CrossRef],8. van Kesteren CFMG, Gremmels H, de Witte LD, et al. Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies. Transl Psychiat. 2017,7(3):e1075. [CrossRef],9. de Souza DF, Wartchow K, Hansen F, et al. Interleukin 6-induced S100B secretion is inhibited by haloperidol and risperidone. Prog Neuro-Psychoph. 2013,43:14-22. [CrossRef],10. Rehn AE, Rees SM. Investigating the neurodevelopmental hypothesis of schizophrenia. Clin Exp Pharmacol. 2005,32(9):687-696. [CrossRef],11. Fusar-Poli P, Smieskova R, Serafini G, Politi P, Borgwardt S. Neuroanatomical markers of genetic liability to psychosis and first episode psychosis: a voxelwise meta-analytical comparison. World J Biol Psych. 2014,15(3):219-228. [CrossRef],12. Faraz S, Pannullo S, Rosenblum M, Smith A, Wernicke AG. Long-term survival in a patient with glioblastoma on antipsychotic therapy for schizophrenia: a case report and literature review. Ther Adv Med Oncol. 2016,8(6):421- 428. [CrossRef],13. Gao XC, Mi YJ, Guo N, et al. Glioma in schizophrenia: is the risk higher or lower? Front Cell Neurosci. 2018,12:289. [CrossRef],14. Di Lullo E, Kriegstein AR. The use of brain organoids to investigate neural development and disease. Nat Rev Neurosci. 2017,18(10):573-584. [CrossRef],15. Iacopino F, Angelucci C, Piacentini R, et al. Isolation of cancer stem cells from three human glioblastoma cell lines: characterization of two selected clones. PLoS ONE. 2014,9(8):e105166. [CrossRef],16. Coyle DE. Adaptation of C6 glioma-cells to serum-free conditions leads to the expression of a mixed astrocyte oligodendrocyte phenotype and increased production of neurite-promoting activity. J Neurosci Res. 1995,41(3):374-385. [CrossRef],17. Aldo PB, Craveiro V, Guller S, Mor G. Effect of culture conditions on the phenotype of THP-1 monocyte cell line. Am J Reprod Immunol. 2013,70(1):80-86. [CrossRef],18. Lancaster MA, Knoblich JA. Generation of cerebral organoids from human pluripotent stem cells. Nat Protoc. 2014,9(10):2329-2340. [CrossRef],19. Mansour AA, Gonçalves JT, Bloyd CW, et al. An in vivo model of functional and vascularized human brain organoids (vol 36, pg 432, 2018). Nat Biotechnol. 2018,36(8):772. [CrossRef],20. Bahuguna A, Khan I, Bajpai VK, Kang SC. MTT assay to evaluate the cytotoxic potential of a drug. Bangl J Pharmacol. 2017,12(2):115-118. [CrossRef],21. Drost J, Karthaus WR, Gao D, et al. Organoid culture systems for prostate epithelial and cancer tissue. Nat Protoc. 2016,11(2):347-358. [CrossRef],22. Blanco S, Bandiera R, Popis M, et al. Stem cell function and stress response are controlled by protein synthesis. Nature. 2016,534(7607):335-340. [CrossRef],23. Somuncu S, Somuncu ÖS, Ballıca B, Tabandeh B. Deficiency of epithelial-mesenchymal transition causes child indirect inguinal hernia. J Pediatr Surg. 2020,55(4):665-671. [CrossRef],24. Schnack L, Sohrabi Y, Lagache S, et al. Mechanisms of trained innate immunity in Oxldl and Bcg primed human coronary smooth muscle cells. Atherosclerosis. 2019,287:e24-e25. [CrossRef],25. Park JB. N-Caffeoyltryptamine, a potent anti inflammatory phenolic amide, suppressed MCP-1 expression in LPS-stimulated THP-1 cells and rats fed a high-fat diet. Int J Mol Sci. 2017,18(6):1148., PMID: 28555020 [CrossRef],26. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci. 1993,84(4):407- 412. [CrossRef],27. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005,38(12):1103-1111. [CrossRef],28. Somuncu ÖS, Coşkun Y, Ballica B, Temiz AF, Somuncu D. In vitro artificial skin engineering by decellularized placental scaffold for secondary skin problems of meningomyelocele. J Clin Neurosci. 2019,59:291-297. [CrossRef],29. labi BR, LaRanger R, Shay J, W. Decellularized mice colons as models to study the contribution of the extracellular matrix to cell behavior and colon cancer progression. Acta Biomater. 2019,100:213-222.,30. Babicki S, Arndt D, Marcu A, et al. Heatmapper: web enabled heat mapping for all. Nucleic Acids Res. 2016,44(W1):W147-W153. [CrossRef],31. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiat. 1994,151(6):825-835. [CrossRef],32. Hendouei N, Saghafi F, Shadfar F, Hosseinimehr SJ. Molecular mechanisms of anti-psychotic drugs for improvement of cancer treatment. Eur J Pharmacol. 2019,856:172402. [CrossRef],33. Borovcanin MM, Jovanovic I, Radosavljevic G, et al. Interleukin-6 in schizophrenia – is there a therapeutic relevance? Front Psychiatry. 2017,8:221. [CrossRef],34. Ajami A, Abedian F, Hosseini SH et al. Serum TNF-α, IL-10 and IL-2 in schizophrenic patients before and after treatment with risperidone and clozapine. Iran J Immunol. 2014,11(3):200-209. [CrossRef],35. Borovcanin M, Jovanovic I, Dejanovic SD et al. Possible role of TGF-beta pathways in schizophrenia. Serb J Exp Clin Res. 2015,17(1):3-8. [CrossRef],36. Borovcanin M, Jovanovic I, Radosavljevic G, et al. Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response. Schizophr Res. 2013,147(1):103-109. [CrossRef],37. Liu XQ, Su P, Meng SS, et al. Role of matrix metalloproteinase-2/9 (MMP2/9) in lead-induced changes in an in vitro blood-brain barrier model. Int J Biol Sci. 2017,13(11):1351-1360. [CrossRef],38. Rempe RG, HartzAMS, Bauer B. Matrix metalloproteinases in the brain and blood-brain barrier: versatile breakers and makers. J Cerebr Blood Met. 2016,36(9):1481-1507. [CrossRef],39. Domenici E, Willé DR, Tozzi F, et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS ONE. 2010,5(2):e9166. [CrossRef],40. Agarwal AB, Christensen AJ, Feng CY et al. Expression of schizophrenia biomarkers in extraocular muscles from patients with strabismus: an explanation for the link between exotropia and schizophrenia? PeerJ. 2017,5:e4214. [CrossRef],41. Keilhoff G, Grecksch G, Bernstein HG, Roskoden T, Becker A. Risperidone and haloperidol promote survival of stem cells in the rat hippocampus. Eur Arch Psy Clin,260(2):151-162. [CrossRef],42. Fu C, Chen D, Chen RJ, Hu QS, Wang GH. The schizophrenia-related protein dysbindin-1A is degraded and facilitates NF-kappa B activity in the nucleus. PLoS ONE. 2015,10(7):e0132639. [CrossRef],43. Steiner J, Bernstein HG, Schiltz K, et al. Immune system and glucose metabolism interaction in schizophrenia: a chicken-egg dilemma. Prog Neuro-Psychoph. 2014,48:287-294. [CrossRef],44. Merenlender-Wagner A, Malishkevich A, Shemer Z, et al. Autophagy has a key role in the pathophysiology of schizophrenia. Mol Psychiatr. 2015,20(1):126-132. [CrossRef],45. Vucicevic L, Misirkic-Marjanovic M, Harhaji-Trajkovic L, Maric N, Trajkovic V. Mechanisms and therapeutic significance of autophagy modulation by antipsychotic Q7 drugs. Cell Stress. 2018,2(11):282-291. [CrossRef],46. Woods AG, Sokolowska I, Taurines R, et al. Potential biomarkers in psychiatry: focus on the cholesterol system. J Cell Mol Med. 2012,16(6):1184-1195. [CrossRef],47. van Nimwegen LJ, Storosum JG, Blumer RM, et al. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab. 2008,93(2):572- 577. [CrossRef],48. Murashita M, Inoue T, Kusumi I, et al. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiat Clin Neuros. 2007,61(1):54-58. [CrossRef],49. Marques JG, Pedro I, Ouakinin S. Unconjugated bilirubin and acute psychosis: a five years retrospective observational and controlled study in patients with schizophrenia, schizoaffective and bipolar disorders. Int J Psychiat Clin. 2019,23(4):281-285., PMID: 31335268 [CrossRef],50. Noto C, Ota VK, Gadelha A, et al. Oxidative stress in drug naive first episode psychosis and antioxidant effects of risperidone. J Psychiatr Res. 2015,68:210-216. [CrossRef],51. Virit O, Altindag A, Yumru M, et al. A defect in the antioxidant defense system in schizophrenia. Neuropsychobiology. 2009,60(2):87-93. [CrossRef] 52. Chertkow Y, Weinreb O, Youdim MBH, Silver H. Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine. Prog Neuro-Psychoph. 2007,31(7):1356-1362. [CrossRef],53. Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatr. 2001,6(3):293-301. [CrossRef],54. Wang XK, Huang KT, Zeng XM, et al. Diagnostic and prognostic value of mRNA expression of phospholipase C beta family genes in hepatitis B virus-associated hepatocellular carcinoma. Oncol Rep. 2019,41(5):2855- 2875. [CrossRef],55. Yang YR, Jung JH, Kim SJ, et al. Forebrain-specific ablation of phospholipase C gamma 1 causes manic-like behavior. Mol Psychiatr. 2017,22(10):1473-1482. [CrossRef]
dspace.entity.typePublication
local.indexed.atTRDizin

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Modeling Schizophrenia with Glioblastoma Cells In Vitro Analysis of Risperidone Treatment on Glial Spheroids.pdf
Size:
3.91 MB
Format:
Adobe Portable Document Format
Download

Collections

TR-Dizin İndeksli Yayınlar Koleksiyonu